Immunoassay for Neurological Biomarkers Market Share Analysis Report, 2023-2032
The global immunoassay for neurological biomarkers market size was exhibited at USD 602.9 million in 2022 and is projected to hit around USD 3,128.84 million by 2032, growing at a CAGR of 17.9% during the forecast period 2023 to 2032.
Key Pointers:
Immunoassay for Neurological Biomarkers Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 710.82 million |
|
Market Size by 2032 |
USD 3,128.84 million |
|
Growth Rate from 2023 to 2032 |
CAGR of 17.9% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Product, Disease, Application |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
QIAGEN; Abbott; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; Sysmex Corporation; Merck KGaA; F. Hoffmann La-Roche Ltd.; Nimble Therapeutics |
The Usage of immunoassays for neurological biomarker testing is likely to witness significant growth during the forecast period owing to increasing prevalence of neurological diseases, growing awareness regarding biomarker usage, and extensive R&D activities as well as ongoing advancements to improve the sensitivity of kits & instruments to measure diagnostic biomarkers.
Biomarkers play a crucial role in selecting appropriate therapies and tracking disease progression. This can be evidenced by research initiatives and clinical studies that are being conducted in hospitals for developing biomarker tests, which, in turn, is anticipated to fuel market growth. For instance, Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau is studying circulating microparticles to develop new biomarkers for neurological prognosis of patients.
Moreover, advancements in technologies help in the identification of early signs related to neurological disorders by detecting biomarkers in serum and blood. Some of the multiplexed immunoassay technologies include Olink's Proximity Extension Assay (PEA) and Quanterix's Simoa. Simoa is based on digitizing ELISA, which allows quantifying biomarkers in both blood and CSF, whereas PEA is based on nucleic acid technologies, helps prevent antibody cross-reactivity with immunoassay.
The rising number of disease-modifying therapies for neurological disorders is boosting the demand for immunoassays for biomarker testing in the market. For instance, in June 2021, the FDA granted accelerated approval to Aduhelm indicated for Alzheimer’s disease. Similarly, in January 2023, the FDA approved Alzheimer’s drug Leqembi (lecanemab). In addition, there are a number of disease-modifying therapies under clinical investigation, which are expected to be launched in the coming years, thereby creating lucrative growth opportunities for market players. For instance, as of November 2022, Roche’s RO7046015, indicated for Parkinson’s disease, is under phase II trial.
Furthermore, the government is undertaking various initiatives to provide better facilities, such as reimbursement for neurological diagnostic tests, which is likely to drive the market. Many healthcare institutions are working with laboratories to integrate different tests. High awareness about blood-based biomarker tests, a rise in the demand for affordable services, and technological advancements are some of the key factors expected to boost the market growth.
On the other hand, technological advancements are leading to an increase in the adoption of molecular diagnostics. Molecular diagnostics are based on the detection and amplification of nucleic acids, and these tests are more sensitive & provide specific results. As a result, the introduction of various quantitative and qualitative molecular assays, such as real-time PCR, LAMP-PCR, multiplex PCR, & digital PCR, that are capable of detecting low levels of analytes are expected to limit the demand of immunoassays for neurological biomarkers during the forecast period.
Immunoassay for Neurological Biomarkers Market Segmentation
| By Product | By Disease | By Application |
|
|
|
Chapter 1 Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Regional Scope
1.1.2 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Nova one advisor Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
Chapter 3 Immunoassays For Neurological Biomarkers Market: Segment Analysis, by Product, 2020 - 2032
3.1 Definition and Scope
3.2 Product Market Share Analysis, 2023 & 2032
3.3 Segment Dashboard
3.4 Global Immunoassays for Neurological Biomarkers Market, by Product, 2020 to 2032
3.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
3.5.1 Instruments
3.5.1.1 Instruments Market, 2020 - 2032
3.5.2 Reagents
3.5.2.1 Reagents Market, 2020 - 2032
3.5.3 Services
3.5.3.1 Services Market, 2020 - 2032
Chapter 4 Immunoassays for Neurological Biomarkers Market: Segment Analysis, by Disease, 2020 - 2032
4.1 Definition and Scope
4.2 Disease Market Share Analysis, 2023 & 2032
4.3 Segment Dashboard
4.4 Global Immunoassays for Neurological Biomarkers Market, by Disease, 2020 to 2032
4.5 Market Size & Forecasts and Trend Analyses, 2020 to 2032
4.5.1 Alzheimer’s Disease
4.5.1.1 Alzheimer’s Disease Market, 2020 - 2032
4.5.2 Parkinson’s Disease
4.5.2.1 Parkinson’s Disease Market, 2020 - 2032
4.5.3 Multiple Sclerosis
4.5.3.1 Multiple Sclerosis Market, 2020 - 2032
4.5.4 Others
4.5.4.1 Others Market, 2020 - 2032
Chapter 5 Immunoassays For Neurological Biomarkers Market: Segment Analysis, By Application, 2020 - 2032
5.1 Definition And Scope
5.2 Application Market Share Analysis, 2023 & 2032
5.3 Segment Dashboard
5.4 Immunoassays For Neurological Biomarkers Market, By Application, 2020 To 2032
5.5 Market Size & Forecasts And Trend Analyses, 2020 To 2032
5.5.1 In Vitro Diagnostics Application
5.5.1.1 In Vitro Diagnostics Application Market, 2020 - 2032
5.5.2 Research Application
5.5.2.1 Research Application Market, 2020 - 2032
Chapter 6 Immunoassays For Neurological Biomarkers Market: Regional Estimates And Trend Analysis, By Product, Disease, & Application
6.1 North America
6.1.1 Swot Analysis
6.1.1.1 North America Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.1.2 U.S.
6.1.2.1 Key Country Dynamics
6.1.2.2 Target Disease Prevalence
6.1.2.3 Competitive Scenario
6.1.2.4 Regulatory Framework
6.1.2.5 Reimbursement Scenario
6.1.2.6 U.S. Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.1.3 Canada
6.1.3.1 Key Country Dynamics
6.1.3.2 Target Disease Prevalence
6.1.3.3 Competitive Scenario
6.1.3.4 Regulatory Framework
6.1.3.5 Reimbursement Scenario
6.1.3.6 Canada Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.2 Europe
6.2.1 Swot Analysis
6.2.1.1 Europe Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.2.2 Germany
6.2.2.1 Key Country Dynamics
6.2.2.2 Target Disease Prevalence
6.2.2.3 Competitive Scenario
6.2.2.4 Regulatory Framework
6.2.2.5 Reimbursement Scenario
6.2.2.6 Germany Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.2.3 U.K.
6.2.3.1 Key Country Dynamics
6.2.3.2 Target Disease Prevalence
6.2.3.3 Competitive Scenario
6.2.3.4 Regulatory Framework
6.2.3.5 Reimbursement Scenario
6.2.3.6 U.K. Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.2.4 France
6.2.4.1 Key Country Dynamics
6.2.4.2 Target Disease Prevalence
6.2.4.3 Competitive Scenario
6.2.4.4 Regulatory Framework
6.2.4.5 Reimbursement Scenario
6.2.4.6 France Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.2.5 Italy
6.2.5.1 Key Country Dynamics
6.2.5.2 Target Disease Prevalence
6.2.5.3 Competitive Scenario
6.2.5.4 Regulatory Framework
6.2.5.5 Reimbursement Scenario
6.2.5.6 Italy Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.2.6 Spain
6.2.6.1 Key Country Dynamics
6.2.6.2 Target Disease Prevalence
6.2.6.3 Competitive Scenario
6.2.6.4 Regulatory Framework
6.2.6.5 Reimbursement Scenario
6.2.6.6 Spain Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.2.7 Denmark
6.2.7.1 Key Country Dynamics
6.2.7.2 Target Disease Prevalence
6.2.7.3 Competitive Scenario
6.2.7.4 Regulatory Framework
6.2.7.5 Reimbursement Scenario
6.2.7.6 Denmark Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.2.8 Sweden
6.2.8.1 Key Country Dynamics
6.2.8.2 Target Disease Prevalence
6.2.8.3 Competitive Scenario
6.2.8.4 Regulatory Framework
6.2.8.5 Reimbursement Scenario
6.2.8.6 Sweden Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.2.9 Norway
6.2.9.1 Key Country Dynamics
6.2.9.2 Target Disease Prevalence
6.2.9.3 Competitive Scenario
6.2.9.4 Regulatory Framework
6.2.9.5 Reimbursement Scenario
6.2.9.6 Norway Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.2.10 Rest Of Europe Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.3 Asia Pacific
6.3.1 Swot Analysis
6.3.1.1 Asia Pacific Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.3.2 Japan
6.3.2.1 Key Country Dynamics
6.3.2.2 Target Disease Prevalence
6.3.2.3 Competitive Scenario
6.3.2.4 Regulatory Framework
6.3.2.5 Reimbursement Scenario
6.3.2.6 Japan Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.3.3 China
6.3.3.1 Key Country Dynamics
6.3.3.2 Target Disease Prevalence
6.3.3.3 Competitive Scenario
6.3.3.4 Regulatory Framework
6.3.3.5 Reimbursement Scenario
6.3.3.6 China Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.3.4 India
6.3.4.1 Key Country Dynamics
6.3.4.2 Target Disease Prevalence
6.3.4.3 Competitive Scenario
6.3.4.4 Regulatory Framework
6.3.4.5 Reimbursement Scenario
6.3.4.6 India Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.3.5 South Korea
6.3.5.1 Key Country Dynamics
6.3.5.2 Target Disease Prevalence
6.3.5.3 Competitive Scenario
6.3.5.4 Regulatory Framework
6.3.5.5 Reimbursement Scenario
6.3.5.6 South Korea Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.3.6 Australia
6.3.6.1 Key Country Dynamics
6.3.6.2 Target Disease Prevalence
6.3.6.3 Competitive Scenario
6.3.6.4 Regulatory Framework
6.3.6.5 Reimbursement Scenario
6.3.6.6 Australia Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.3.7 Thailand
6.3.7.1 Key Country Dynamics
6.3.7.2 Target Disease Prevalence
6.3.7.3 Competitive Scenario
6.3.7.4 Regulatory Framework
6.3.7.5 Reimbursement Scenario
6.3.7.6 Thailand Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.3.8 Rest Of Asia Pacific Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.4 Latin America
6.4.1 Swot Analysis
6.4.1.1 Latin America Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.4.2 Brazil
6.4.2.1 Key Country Dynamics
6.4.2.2 Target Disease Prevalence
6.4.2.3 Competitive Scenario
6.4.2.4 Regulatory Framework
6.4.2.5 Reimbursement Scenario
6.4.2.6 Brazil Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.4.3 Mexico
6.4.3.1 Key Country Dynamics
6.4.3.2 Target Disease Prevalence
6.4.3.3 Competitive Scenario
6.4.3.4 Regulatory Framework
6.4.3.5 Reimbursement Scenario
6.4.3.6 Mexico Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.4.4 Argentina
6.4.4.1 Key Country Dynamics
6.4.4.2 Target Disease Prevalence
6.4.4.3 Competitive Scenario
6.4.4.4 Regulatory Framework
6.4.4.5 Reimbursement Scenario
6.4.4.6 Argentina Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.4.5 Rest Of Latam Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.5 Middle East & Africa (MEA)
6.5.1 Swot Analysis
6.5.1.1 Middle East & Africa Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.5.2 South Africa
6.5.2.1 Key Country Dynamics
6.5.2.2 Target Disease Prevalence
6.5.2.3 Competitive Scenario
6.5.2.4 Regulatory Framework
6.5.2.5 Reimbursement Scenario
6.5.2.6 South Africa Immunoassay For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.5.3 Saudi Arabia
6.5.3.1 Key Country Dynamics
6.5.3.2 Target Disease Prevalence
6.5.3.3 Competitive Scenario
6.5.3.4 Regulatory Framework
6.5.3.5 Reimbursement Scenario
6.5.3.6 Saudi Arabia Immunoassay For Neurological Biomarkers
6.5.3.7 Market Estimates And Forecasts, 2020 - 2032
6.5.4 UAE
6.5.4.1 Key Country Dynamics
6.5.4.2 Target Disease Prevalence
6.5.4.3 Competitive Scenario
6.5.4.4 Regulatory Framework
6.5.4.5 Reimbursement Scenario
6.5.4.6 Uae Immunoassay For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.5.5 Kuwait
6.5.5.1 Key Country Dynamics
6.5.5.2 Target Disease Prevalence
6.5.5.3 Competitive Scenario
6.5.5.4 Regulatory Framework
6.5.5.5 Reimbursement Scenario
6.5.5.6 Kuwait Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
6.5.6 Rest Of MEA Immunoassays For Neurological Biomarkers Market Estimates And Forecasts, 2020 - 2032
Chapter 7 Immunoassays For Neurological Biomarkers Market: Competitive Landscape
7.1 QIAGEN
7.2 Abbott
7.3 Merck & Co., Inc.
7.4 Johnson & Johnson Services, Inc.
7.5 Thermo Fisher Scientific, Inc.
7.6 Bio-Rad Laboratories, Inc.
7.7 Sysmex Corporation
7.8 Merck KGaA
7.9 F. Hoffmann La-Roche Ltd.
7.10 Nimble Therapeutics
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers